Guangzhou Kingmed Diagnostics Group Past Earnings Performance
Past criteria checks 1/6
Guangzhou Kingmed Diagnostics Group has been growing earnings at an average annual rate of 0.1%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 8.7% per year. Guangzhou Kingmed Diagnostics Group's return on equity is 1.9%, and it has net margins of 2.1%.
Key information
0.1%
Earnings growth rate
-0.2%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 8.7% |
| Return on equity | 1.9% |
| Net Margin | 2.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06
Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Recent updates
Guangzhou Kingmed Diagnostics Group (SHSE:603882) Has A Pretty Healthy Balance Sheet
Dec 13Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06Earnings Tell The Story For Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Sep 27Guangzhou Kingmed Diagnostics Group Co., Ltd. Just Missed Revenue By 9.5%: Here's What Analysts Think Will Happen Next
Sep 03Is Guangzhou Kingmed Diagnostics Group (SHSE:603882) Using Too Much Debt?
Aug 25A Look At The Fair Value Of Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)
Jun 04Guangzhou Kingmed Diagnostics Group's (SHSE:603882) Shareholders Have More To Worry About Than Only Soft Earnings
May 02Investors Don't See Light At End Of Guangzhou Kingmed Diagnostics Group Co., Ltd.'s (SHSE:603882) Tunnel And Push Stock Down 26%
Apr 17Investor Optimism Abounds Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) But Growth Is Lacking
Feb 28Revenue & Expenses Breakdown
How Guangzhou Kingmed Diagnostics Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 7,849 | 161 | 2,154 | 404 |
| 30 Jun 24 | 8,251 | 448 | 2,188 | 410 |
| 31 Mar 24 | 8,263 | 475 | 2,231 | 428 |
| 31 Dec 23 | 8,540 | 643 | 2,218 | 467 |
| 30 Sep 23 | 9,578 | 882 | 2,349 | 541 |
| 30 Jun 23 | 11,052 | 1,397 | 2,465 | 583 |
| 31 Mar 23 | 13,342 | 2,054 | 2,525 | 622 |
| 31 Dec 22 | 15,476 | 2,755 | 2,761 | 633 |
| 30 Sep 22 | 15,534 | 2,996 | 2,807 | 613 |
| 30 Jun 22 | 14,800 | 2,803 | 2,734 | 597 |
| 31 Mar 22 | 13,516 | 2,532 | 2,648 | 554 |
| 31 Dec 21 | 11,943 | 2,220 | 2,394 | 518 |
| 30 Sep 21 | 11,034 | 2,127 | 2,188 | 471 |
| 30 Jun 21 | 10,225 | 2,013 | 2,014 | 443 |
| 31 Mar 21 | 9,752 | 2,000 | 1,869 | 434 |
| 31 Dec 20 | 8,244 | 1,510 | 1,660 | 397 |
| 30 Sep 20 | 7,176 | 1,138 | 1,461 | 381 |
| 30 Jun 20 | 6,201 | 787 | 1,372 | 359 |
| 31 Mar 20 | 5,276 | 408 | 1,289 | 333 |
| 31 Dec 19 | 5,269 | 402 | 1,312 | 324 |
| 30 Sep 19 | 5,128 | 388 | 1,275 | 303 |
| 30 Jun 19 | 4,954 | 309 | 1,242 | 293 |
| 31 Mar 19 | 4,771 | 266 | 1,214 | 281 |
| 31 Dec 18 | 4,525 | 233 | 1,156 | 291 |
| 30 Sep 18 | 4,309 | 205 | 1,142 | 284 |
| 30 Jun 18 | 4,107 | 200 | 974 | 398 |
| 31 Mar 18 | 3,909 | 191 | 1,007 | 326 |
| 31 Dec 17 | 3,792 | 189 | 1,043 | 256 |
| 30 Sep 17 | 3,689 | 198 | 1,066 | 191 |
| 31 Dec 16 | 3,222 | 170 | 1,141 | 0 |
| 30 Sep 16 | 3,010 | 153 | 1,087 | 0 |
| 31 Dec 15 | 2,389 | 140 | 891 | 0 |
| 31 Dec 14 | 1,838 | 71 | 731 | 0 |
| 31 Dec 13 | 1,356 | 52 | 507 | 0 |
Quality Earnings: 603882 has a large one-off gain of CN¥75.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 603882's current net profit margins (2.1%) are lower than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603882's earnings have grown by 0.1% per year over the past 5 years.
Accelerating Growth: 603882's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603882 had negative earnings growth (-81.7%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).
Return on Equity
High ROE: 603882's Return on Equity (1.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:47 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Kingmed Diagnostics Group Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hao Wu | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |